Lever
Lifestyle
- Increase physical activity
- Quit smoking
- Maintain a healthy weight
Blutwerte · Marker
Apolipoprotein A1
ApoA1 · Apo A-I
Lipide & Herz-Kreislauf
- Einheit:
- g/L
- Abbreviation
- ApoA1
Apolipoprotein A1 quantifies the primary protein component of HDL involved in cholesterol transport.
Reference Ranges
Reference
1.04–2.14g/L
1.04
1.2
2
2.14
LowNormalHigh
Reference
Optimal
Unit · g/LRanges may vary slightly by laboratory; typically higher in females.
Overview
Übersicht
Apolipoprotein A1 (ApoA1) is the primary protein component of high-density lipoprotein (HDL) in plasma. It plays a crucial role in lipid metabolism by facilitating the efflux of cholesterol from tissues to the liver for excretion, a process known as reverse cholesterol transport. Researchers have found that ApoA1 is integral to HDL's structure and function, contributing to its anti-atherogenic properties. Clinically, ApoA1 levels are used as a biomarker for cardiovascular health, with higher levels generally indicating a lower risk of coronary artery disease. It is also involved in the acute phase response and immune modulation. In the context of athletic performance and biohacking, ApoA1 is of interest due to its role in lipid metabolism and potential impact on cardiovascular efficiency and longevity. Some researchers suggest that optimizing ApoA1 levels could support improved cardiovascular health and endurance. However, factors such as genetic predisposition, lifestyle, and dietary habits can influence ApoA1 levels. Testing for ApoA1 does not typically require fasting, but levels can be affected by acute illness, inflammation, and certain medications, which should be considered when interpreting results.
Klinische Bedeutung
Elevated ApoA1 levels are generally associated with a reduced risk of cardiovascular disease, while low levels may indicate increased risk. It reflects the efficiency of reverse cholesterol transport and overall lipid metabolism health.
Dynamics
Trend Interpretation
Rising Values
Progressively rising ApoA1 levels suggest improved cardiovascular health and lipid metabolism. Re-test annually to monitor trends.
Falling Values
Progressively falling ApoA1 levels may indicate worsening cardiovascular risk or metabolic health.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Regular physical activity
- Estrogen therapy
- Moderate alcohol consumption
- Genetic factors
- High HDL cholesterol levels
Cause
Low Levels
- Smoking
- Obesity
- Sedentary lifestyle
- Metabolic syndrome
- Chronic inflammation
Protocol
How to Optimize
Lever
Nutrition
- Consume omega-3 fatty acids
- Include nuts and seeds
- Eat a diet rich in fruits and vegetables
Lever
Supplementation
- Niacin
- Omega-3 fish oil
Note:
Consult a healthcare provider before starting any new supplement regimen.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for those at risk of cardiovascular disease
Interfering Factors
- Acute illness
- Inflammation
- Certain medications
Related Peptides & Hormones
Hdl Cholesterol
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that reference ranges and optimal targets for Apolipoprotein A1 in various diseases, including heart failure and COVID-19, remain poorly defined. Researchers have not yet established the specific confounders that may affect Apo A1 levels, such as inflammation or co-existing conditions. Additionally, clinical questions remain unanswered regarding the precise role of Apo A1 in disease progression and its potential as a therapeutic target in different patient populations.
60 Research Publications
1,254
Total Citations
42
Human/RCT
5.0
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.
ReviewInfluence32.0
824
This consensus statement evaluated the necessity of fasting for lipid profile determination, concluding that fasting does not significantly affect Apolipoprotein A1 levels. Researchers recommend using non-fasting samples for routine lipid assessments to improve patient compliance.
02Top
#02
Blood-based biomarkers for Parkinson's disease.
ReviewInfluence1.0
141
Researchers discussed the potential of Apolipoprotein A1 (APOA1) as a blood-based biomarker for Parkinson's disease, among other candidates. They highlighted the challenges and advancements in identifying effective biomarkers from blood samples.
03Top
#03
Apolipoprotein A1 and B.
ReviewInfluence1.0
49
This review article highlighted that apolipoprotein A1 and B are superior to traditional cholesterol measures for assessing vascular disease risk and the effectiveness of LDL-lowering therapies. Researchers emphasized their importance in laboratory practice.
04
#04
Serum apolipoprotein A-I depletion is causative to silica nanoparticles-induced cardiovascular damage.
Animal
48
Researchers found that silica nanoparticles can deplete Apolipoprotein A1 (ApoA1) from the bloodstream, leading to cardiovascular damage. The study suggests that maintaining ApoA1 levels may be important for mitigating the toxic effects of nanoparticle exposure.
05
#05
Apolipoproteins as Differentiating and Predictive Markers for Assessing Clinical Outcomes in Patients with Small Cell Lung Cancer.
HumanInfluence1.0
25
This study assessed the expression of Apolipoprotein A1 (ApoA1) in small cell lung cancer (SCLC) patients, finding significant differences compared to other lung cancer types. Researchers suggest ApoA1 may serve as a predictive marker for SCLC outcomes.
06
#06
HDLs and the pathogenesis of atherosclerosis.
Schwertani Adel, et al. · Current opinion in cardiology · 2018
Review
18
This review explored the role of HDL and apolipoprotein A1 in atherosclerosis. Researchers found that HDL's protective functions can be compromised in disease states, suggesting that changes in Apo A-I may contribute to the progression of cardiovascular diseases.
Key findings
- 01Researchers observed that HDL cholesterol levels are not effective therapeutic targets for preventing heart disease.
- 02They found that HDL performs various protective functions against atherosclerosis that are independent of cholesterol levels.
- 03The study identified a protein, desmocollin 1, that may hinder HDL's beneficial roles in heart health.
07
#07
HDL Structure.
Human
16
Researchers examined the structure of high-density lipoprotein (HDL) and its components, highlighting the role of Apolipoprotein A1 (Apo A-I) in HDL function and its involvement in various physiological processes. They found that HDL's composition, including proteins and lipids, significantly influences its biological activities and potential roles in health and disease.
08
#08
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype.
Human
16
Researchers found that higher levels of Apolipoprotein A1 (ApoA1) and HDL cholesterol before and after immunotherapy were associated with better survival outcomes in nasopharyngeal carcinoma patients. This suggests a potential role for ApoA1 in enhancing immunotherapy responses.
09
#09
A study of apolipoprotein A1(ApoA1) and interleukin-10(IL-10) in diabetes with foot ulcers.
HumanInfluence2.0
15
Researchers investigated the association between Apolipoprotein A1 (ApoA1) and diabetic foot ulcers, finding lower levels of ApoA1 in patients with ulcers compared to those without. The study suggests ApoA1 could serve as an early biomarker for assessing ulcer severity.
10
#10
Potential biomarkers in the sera of breast cancer patients from bahawalpur, pakistan.
HumanInfluence1.0
14
This study examined serum proteome expression in breast cancer patients and benign breast disease patients to identify potential biomarkers for diagnosis and prognosis. Researchers found that certain proteins were differentially expressed in breast cancer cases compared to benign conditions, suggesting their potential as diagnostic biomarkers.
Clinical Trials (2)
2
Total Trials
2,050
Total Enrolled
Effects of 10 Weeks of Lifestyle Coaching on Cardiometabolic Risk Factors, Workability and Subjective Wellbeing
NCT04633876UNKNOWN
Sponsor
Aava Medical
Enrollment
2,000
Started
2020
Primary outcome
ApoB/ApoA1
Work Related StressMetabolic SyndromeLipid Metabolism DisordersLifestyle Risk ReductionBurnout
Resveratrol and Serum Apo A-I
NCT01364961COMPLETED
Sponsor
Maastricht University Medical Center
Enrollment
50
Started
2011
Primary outcome
ApoA-I level
Dyslipidemia
Publication Trend
Research publications about Apolipoprotein A1 over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer